1538-1539 / 2063
EGFR inhibition + RCT in rectal cancer
•
Relatively low pCR in pts receiving cetuximab along
with CRT as preop R\ in rectal cancer in phase I/II
25
Machiels Ann Oncol 2007
pCR = 5% (2/37)
pCR = 9% (4/45)
Rödel C Int J Radiat Oncol Biol Phys 2008
Cetuximab, capecitabine, oxaliplating and RT
Cetuximab, capecitabine, and RT